Omalizumab effectiveness is independent of Staphylococcal Enterotoxin sensitization

Visual and bibliometric analysis of chronic rhinosinusitis and nasal polyps

“…We found that C. Bachert also focused on biological studies in 2022, and the latest study in which he participated showed that omalizumab’s effectiveness is independent of Staphylococcal enterotoxin sensitization. 28 Moreover, he also published as the first author of the study of the therapeutic effect of dupilumab and mepolizumab in patients with CRS. 27 , 29 In addition, he constructed a decision tree model through the combination of nasal secretion biomarkers and clinical characteristics of patients with CRS to accurately define patients with type 2 CRS with NPs in a noninvasive way to give more rational treatment to patients in the clinic.…”

“… 30 C. Bachert’s group has focused on various directions, including endotype clustering of patients with CRS on the basis of different molecules, surgery, biological therapies, pathophysiological mechanisms, and so on. 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 Recently, R. P. Schleimer has focused on frontier molecules and treatments such as retinoic acid, nasal secretion tissue plasminogen activator, and oral CRTH2 antagonist. 36 , 37 , 38 However, R. J. Schlosser focused more on olfaction and the surgical treatment of CRS.…”

“…They were all involved in compiling the most co-cited publication in the research of CRS and NPs: European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Interestingly, all 3 authors had recently published research on biologics as first authors 27 , 28 , 42 , 43 (indeed, the updated EPOS 2020 is currently more relevant). As mentioned in the previous article, this fact reaffirmed the importance of biologics research in CRS and NPs research.…”

Visual and bibliometric analysis of Chronic Rhinosinusitis and Nasal Polyps

“…The five authors with the most publications in this study were Bachert Claus, Schleimer Robert P, Schlosser Rodney J, Zhang Luo, and Kern Robert C, with over 80 publications. We searched that Prof. Bachert Claus also focused on biological studies in 2022, and the latest article in which he participated showed that Omalizumab's effectiveness is independent of Staphylococcal Enterotoxin sensitization [28] . Moreover, he also published as the first author of the study of the therapeutic effect of Dupilumab and Mepolizumab in CRS patients [27,29] .…”

“…In addition, he constructed a decision tree model through the combination of nasal secretion biomarkers and clinical characteristics of CRS patients to accurately define type 2 CRSwNP patients in a non-invasive way to give more rational treatment to patients in the clinic [30] . Prof. Bachert Claus' group has focused on various directions, including endotypes clustering of CRS patients based on different molecules, surgery, biological therapies, pathophysiological mechanisms, and so on [28][29][30][31][32][33][34][35] . plasminogen activator, and oral CRTH2 antagonist [36][37][38] .…”